Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study
- 26 November 2008
- journal article
- Published by Springer Nature in Human Genetics
- Vol. 125 (1) , 11-20
- https://doi.org/10.1007/s00439-008-0587-4
Abstract
The human PLA2G7 gene encodes lipoprotein-associated phospholipase A2 (Lp-PLA2), an emerging risk factor for cardiovascular diseases. In the present study, seven single nucleotide polymorphisms (SNPs) in the PLA2G7 gene were genotyped in 827 patients with coronary heart disease (CHD), of which 512 were patients with myocardial infarction (MI), and 947 age- and gender-matched controls in a Chinese Han population. Plasma Lp-PLA2 activity was measured in 416 randomly selected controls and 689 randomly selected CHD patients, including 423 MI patients. Lp-PLA2 activity in CHD and MI cases was significantly higher (233.42 ± 57.66 and 234.27 ± 59.51 nmol ml−1 min−1, respectively) than in controls (211.47 ± 58.61 nmol ml−1 min−1). After adjusting for traditional risk factors by logistic regression, the odds ratios for CHD and MI per 1 standard deviation increment of Lp-PLA2 activity were 1.27 (95% CI, 1.07–1.50) and 1.27 (95% CI, 1.05–1.54), respectively. Both single SNP analysis and haplotype analysis showed that the V279F and I198T polymorphisms were significantly associated with the reduced Lp-PLA2 activity, but neither was associated with increased CHD risk. Both univariate and multivariate analyses, adjusting effects of conventional factors, indicated that the rs13210554 T allele increased the risk of MI in this Chinese Han population. In summary, an independent association of increased plasma Lp-PLA2 activity with CHD and MI existed in this Chinese Han Population. Although V279F and I198T mutations significantly decreased the activity of Lp-PLA2, only the promoter rs13210554 polymorphism was associated with MI. Lp-PLA2 activity appears to influence the CHD and MI risk in Chinese Han population.Keywords
This publication has 27 references indexed in Scilit:
- Prognostic Utility of Lipoprotein-Associated Phospholipase A 2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Comprehensive Evaluation of Genetic and Environmental Factors Influencing the Plasma Lipoprotein-Associated Phospholipase A2 Activity in a Japanese PopulationHypertension Research, 2007
- Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic StrokeCirculation, 2005
- Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) StudyCirculation, 2004
- Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic targetCurrent Opinion in Pharmacology, 2001
- Lipoprotein-Associated Phospholipase A2as an Independent Predictor of Coronary Heart DiseaseNew England Journal of Medicine, 2000
- The Ile198Thr and Ala379Val Variants of Plasmatic Paf-Acetylhydrolase Impair Catalytical Activities and Are Associated with Atopy and AsthmaAmerican Journal of Human Genetics, 2000
- Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthmaJournal of Clinical Investigation, 1999
- A Mutation in Plasma Platelet-Activating Factor Acetylhydrolase (Val 279 →Phe) is a Genetic Risk Factor for StrokeStroke, 1997